Journal of Diagnostics Concepts & Practice ›› 2022, Vol. 21 ›› Issue (05): 560-566.doi: 10.16150/j.1671-2870.2022.05.003
• Original articles • Previous Articles Next Articles
MA Qianchen, ZHANG Benyan, RUI Weiwei, WANG Ting, LUO Fangxiu, WANG Chaofu, YUAN Fei()
Received:
2022-10-20
Online:
2022-10-25
Published:
2023-01-29
Contact:
YUAN Fei
E-mail:daphny2014@163.com
CLC Number:
MA Qianchen, ZHANG Benyan, RUI Weiwei, WANG Ting, LUO Fangxiu, WANG Chaofu, YUAN Fei. Analysis of pathological classification of 3 071 case of gastric cancer in China[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(05): 560-566.
分类 | ICD-0编码 |
---|---|
良性上皮性肿瘤及癌前病变 | |
腺上皮内瘤变,低级别 | 8148/0 |
腺上皮内瘤变,高级别 | 8148/2 |
锯齿状异型增生,低级别 | 8213/0 |
锯齿状异型增生,高级别 | 8213/2 |
肠型异型增生 | |
小凹型(胃型)异型增生 | |
胃隐窝型异型增生 | |
肠型腺瘤,低级别 | 8144/0 |
肠型腺瘤,高级别 | 8144/2 |
散发性肠型胃腺瘤 | |
综合征性肠型胃腺瘤 | |
腺瘤性息肉,低度异型增生 | 8210/0 |
腺瘤性息肉,高度异型增生 | 8210/2 |
恶性上皮性肿瘤 | |
腺癌 | 8140/3 |
管状腺癌 | 8211/3 |
壁细胞癌 | 8214/3 |
混合性腺癌 | 8255/3 |
乳头状腺癌 | 8260/3 |
微乳头状腺癌 | 8265/3 |
黏液表皮样癌 | 8430/3 |
黏液腺癌 | 8480/3 |
印戒细胞癌 | 8490/3 |
低黏附性癌 | 8490/3 |
伴有淋巴样间质的癌 | 8512/3 |
肝样腺癌 | 8576/3 |
潘氏细胞癌 | |
鳞状细胞癌 | 8070/3 |
腺鳞癌 | 8560/3 |
未分化癌 | 8020/3 |
横纹肌样型大细胞癌 | 8014/3 |
多形性癌 | 8022/3 |
肉瘤样癌 | 8033/3 |
破骨样巨细胞癌 | 8035/3 |
胃母细胞瘤 | 8976/1 |
神经内分泌肿瘤 | 8240/3 |
神经内分泌肿瘤,G1 | 8240/3 |
神经内分泌肿瘤,G2 | 8240/3 |
神经内分泌肿瘤,G3 | 8240/3 |
胃泌素瘤 | 8153/3 |
生长抑素瘤 | 8156/3 |
肠嗜铬细胞类癌 | 8241/3 |
恶性肠嗜铬样细胞类癌 | 8242/3 |
神经内分泌癌,NOS | 8246/3 |
大细胞神经内分泌癌 | 8013/3 |
小细胞神经内分泌癌 | 8041/3 |
混合型神经内分泌-非神经内分泌肿瘤 | 8154/3 |
胃癌病理亚型 | 病例数 | 总体构成 比(%) | 亚类构成 比(%) |
---|---|---|---|
腺癌 | 3 003 | 97.79 | / |
管状腺癌*、乳头状腺癌* 和混合型腺癌* | 1 928 | 62.78 | 64.20 |
低黏附性癌* | 867 | 28.23 | 28.87 |
印戒细胞癌△ | 780 | 25.40 | 25.97 |
黏液腺癌# | 179 | 5.83 | 5.96 |
伴有淋巴样间质的癌# | 5 | 0.16 | 0.17 |
肝样腺癌# | 22 | 0.72 | 0.73 |
微乳头状腺癌# | 2 | 6.7 | 0.07 |
黏液表皮样癌# | 0 | 0 | 0 |
壁细胞腺癌# | 0 | 0 | 0 |
潘氏细胞癌# | 0 | 0 | 0 |
鳞状细胞癌 | 4 | 0.13 | / |
腺鳞癌 | 5 | 0.16 | / |
未分化癌 | 1 | 0.03 | / |
胃母细胞瘤 | 0 | 0 | / |
神经内分泌瘤 | 6 | 0.20 | / |
神经内分泌肿瘤,G1 | 1 | 0.03 | 16.67 |
神经内分泌肿瘤,G2 | 2 | 0.07 | 33.33 |
神经内分泌肿瘤,G3 | 3 | 0.10 | 50 |
神经内分泌癌 | 18 | 0.59 | / |
大细胞神经内分泌癌 | 14 | 0.46 | 77.78 |
小细胞神经内分泌癌 | 4 | 0.13 | 22.22 |
混合型神经内分泌- 非神经内分泌肿瘤 | 34 | 1.11 | / |
[1] |
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study[J]. JAMA Oncol, 2019, 5(12):1749-1768.
doi: 10.1001/jamaoncol.2019.2996 pmid: 31560378 |
[2] | Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition)[J/OL]. Gastric Cancer, 2020-02-14[2022-10-20]. https://link.springer.com/article/10.1007/s10120-020-01042-y. |
[3] |
Eom DW, Kang GH, Han SH, et al. Gastric micropapillary carcinoma: a distinct subtype with a significantly worse prognosis in TNM stages Ⅰ and Ⅱ[J]. Am J Surg Pathol, 2011, 35(1):84-91.
doi: 10.1097/PAS.0b013e3181ff61e2 URL |
[4] |
Di Pinto F, Armentano R, Arborea G, et al. Are immunohistochemical markers useful in phenotypic gastric cancer classification?[J]. Oncology, 2020, 98(8):566-574.
doi: 10.1159/000506077 pmid: 32316005 |
[5] | 《胃癌HER2检测指南》编写组. 胃癌HER2检测指南[J]. 中华病理学杂志, 2011, 40(8):553-557. |
Preparation group of Guidelines for HER2 Detection of Gastric Cancer. Guidelines for HER2 detection in gastric cancer[J]. Chin J Pathol, 2011, 40(8):553-557. | |
[6] | The WHO Classification of Tumors Editorial Board. WHO classification of tumours of digestive system tumors[M]. 5th ed. Lyon: IARC press, 2019. |
[7] |
Ilic M, Ilic I. Epidemiology of stomach cancer[J]. World J Gastroenterol, 2022, 28(12):1187-1203.
doi: 10.3748/wjg.v28.i12.1187 URL |
[8] | 王静雷, 杨一兵, 耿云霞, 等. 1990-2017年中国胃癌发病、患病及死亡状况趋势分析[J]. 中国慢性病预防与控制, 2020, 28(5):321-325. |
Wang JL, Yang YB, Geng YX, et al. Trend analysis of the morbidity, prevalence and mortality of stomach cancer in China from 1990 to 2017[J]. Chin J Prev Control Chronic Dis, 2020, 28(5):321-325. | |
[9] |
齐长松, 程思远, 沈琳. 中国胃癌患者三线治疗的现状及研究进展[J]. 中华肿瘤杂志, 2020, 42(12):983-988.
pmid: 33342152 |
Qi CS, Cheng SY, Shen L. Current status and research progress of third-line treatment for patients with gastric cancer in China[J]. Chin J Oncol, 2020, 42(12):983-988.
doi: 10.3760/cma.j.cn112152-20190910-00589 pmid: 33342152 |
|
[10] |
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview[J]. Int J Cancer, 2021, 149(4):778-789.
doi: 10.1002/ijc.33588 URL |
[11] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
doi: 10.3322/caac.21492 URL |
[12] |
Bencivenga M, Treppiedi E, Dal Cero M, et al. The amount of signet ring cells is significantly associated with tumour stage and survival in gastric poorly cohesive tumours[J]. J Surg Oncol, 2020, 121(7):1084-1089.
doi: 10.1002/jso.25885 pmid: 32153051 |
[13] |
Ushiku T, Uozaki H, Shinozaki A, et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas[J]. Cancer Sci, 2009, 100(4):626-632.
doi: 10.1111/j.1349-7006.2009.01108.x URL |
[14] |
Yamazawa S, Ushiku T, Shinozaki-Ushiku A, et al. Gastric cancer with primitive enterocyte phenotype: an aggressive subgroup of intestinal-type adenocarcinoma[J]. Am J Surg Pathol, 2017, 41(7):989-997.
doi: 10.1097/PAS.0000000000000869 pmid: 28505005 |
[15] |
Chen YC, Fang WL, Wang RF, et al. Clinicopathological variation of lauren classification in gastric cancer[J]. Pathol Oncol Res, 2016, 22(1):197-202.
doi: 10.1007/s12253-015-9996-6 URL |
[16] |
Kushima R. The updated WHO classification of digestive system tumours-gastric adenocarcinoma and dysplasia[J]. Pathologe, 2022, 43(1):8-15.
doi: 10.1007/s00292-021-01023-7 URL |
[17] |
Polom K, Marano L, Marrelli D, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer[J]. Br J Surg, 2018, 105(3):159-167.
doi: 10.1002/bjs.10663 pmid: 29091259 |
[18] |
Cho J, Kang SY, Kim KM. MMR protein immunohistochemistry and microsatellite instability in gastric cancers[J]. Pathology, 2019, 51(1):110-113.
doi: 10.1016/j.pathol.2018.09.057 URL |
[19] |
Zhang L, Wang Y, Li Z, et al. Clinicopathological features of tumor mutation burden, Epstein-barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer[J]. Diagn Pathol, 2021, 16(1):38.
doi: 10.1186/s13000-021-01099-y pmid: 33933102 |
[20] |
Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma[J]. Am J Pathol, 1992, 140(4):769-774.
pmid: 1314023 |
[21] | 刘莹, 臧凤琳, 邱志强, 等. 886例胃腺癌患者错配修复蛋白表达和EB病毒感染状态与其临床病理特征的关系[J]. 中华胃肠外科杂志, 2021, 24(5):440-448. |
Liu Y, Zang FL, Qiu ZQ, et al. Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients[J]. Chin J Gastrointest Surg, 2021, 24(5):440-448. | |
[22] | 《胃癌HER2检测指南(2016版)》专家组. 胃癌HER2检测指南(2016版)[J]. 中华病理学杂志, 2016, 45(8):528-532. |
Guideline Recommendations for HER2 Detection in Gastric Cancer Group. Guidelines for HER2 detection in gastric cancer(2016)[J]. Chin J Pathol, 2016, 45(8):528-532. | |
[23] |
Suh YS, Na D, Lee JS, et al. Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal Junction between esophageal and gastric adenocarcinomas[J]. Ann Surg, 2022, 275(4):706-717.
doi: 10.1097/SLA.0000000000004303 URL |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||